While there has been longstanding and recognized value of PSMA for the diagnosis and therapeutic management of PCA in people, it has been debatable if PSMA is uniformly and overexpressed in urothelial carcinomas of the bladder in human beings [38]. This evidence concerns the gene FOLH1 and bladder transitional cell carcinoma.